Amgen investigational therapy for bone loss, denosumab, show increased bone mineral density
...unced that twice-yearly subcutaneous injections of denosumab (60 mg), (previously referred to as AMG 162), incr...ompleted two years of study. Researchers reported denosumab 60mg increased BMD of the lumbar spine by 7.4 percent in women administered the therapy twice yearly...